PLUS1
7.86
-0.11 (-1.38%)
-0.11 (-1.38%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Acorda Therapeutics Inc | ACOR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.11 | -1.38% | 7.86 | 05:54:40 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.97 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 7.91 | 8.40 | 0.49 | - | - |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 11 | 501 | 1,846,743 | 2.412 - 15.30 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 05:54:40 | 20 | $ 7.90 | USD |
Acorda Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 74.54M | 9.48M | 8.53M | $ 192.41M | $ -27.73M | -34.50 | 1.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Acorda Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/15/2021 | 20:19 | TipRanks | Acorda Stock at $35 a Share? This Analyst Thinks It’s.. |
| 1/13/2021 | 07:31 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 1/13/2021 | 07:13 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/12/2021 | 16:07 | Business Wire | Acorda Therapeutics to Present at 39th Annual J.P. Morgan.. |
| 1/11/2021 | 16:20 | Business Wire | Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT.. |
| 12/31/2020 | 16:19 | Business Wire | Acorda Therapeutics Announces Completion of One-for-Six.. |
| 12/10/2020 | 09:10 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACOR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.16 | 8.40 | 5.50 | 6.28 | 10,833,187 | 0.70 | 9.78% |
| 1 Month | 4.20 | 8.40 | 3.37 | 5.50 | 4,081,797 | 3.66 | 87.14% |
| 3 Months | 5.2032 | 8.40 | 3.37 | 5.16 | 3,552,299 | 2.66 | 51.06% |
| 6 Months | 4.44 | 9.84 | 2.412 | 4.69 | 4,584,058 | 3.42 | 77.03% |
| 1 Year | 12.48 | 15.30 | 2.412 | 5.34 | 3,227,184 | -4.62 | -37.02% |
| 3 Years | 164.70 | 218.10 | 2.412 | 27.53 | 1,788,705 | -156.84 | -95.23% |
| 5 Years | 221.16 | 243.4194 | 2.412 | 51.25 | 1,366,565 | -213.30 | -96.45% |
Acorda Therapeutics Description
| Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States. |
